Vupanorsen Falls Short Despite HDL-C Reduction in TRANSLATE-TIMI 70 - MD Magazine

Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.

Antisense oligonucleotide ANGTYL3 inhibitor vupanorsen provided significant reduction of non-high-density lipoprotein cholesterol (HDL-C) in adults with hyperlipidemia at 24 weeks. The late-breaking… [+2263 chars]

full article...